Harnessing the power of cTRLs (circulating tumor-reactive lymphocytes) in the blood to unlock the next generation of solid tumor cancer therapies.
Related news
FACIT investment in cTRL Therapeutics focuses cell therapy R&D on Ontario for patients with cancer
cTRL Therapeutics announced it is strengthening its research and development operations in Canada. Following an investment by FACIT, the company will establish a state-of-the-art laboratory and leverage Ontario’s world-leading cancer research network to accelerate advancement of its cancer therapeutics pipeline to benefit patients sooner. Read More
cTRL Therapeutics announces new Chief Executive Officer to continue advancing its novel immune cell therapy
cTRL Therapeutics ("cTRL"), a FACIT co-founded and financed company developing novel tumour cell therapies for patients living with cancer, welcomes industry veteran Derrell D. Porter, M.D., as Chief Executive Officer. Read More
CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer
CTRL Therapeutics ("CTRL") closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer. Read More
FACIT generates $1.5 billion in follow-on investment
FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada. Read More
FACIT and University of Toronto launch precision medicine company: Cellular Analytics
October 30, 2019 – Cellular Analytics is founded upon a proprietary microfluidic platform that enables molecular characterization of cancer at the level of single circulating tumour cells. Read More
FACIT welcomes life sciences executive Ken Newport to its Board; Director Shana Kelley appointed to the Order of Ontario
January 26, 2021 – Mr. Newport is a passionate executive and advocate of Ontario’s life science sector, having decades of leadership experience in both public and private ventures. Read More
High-potency TIL cell therapy approach reported using CytoFind platform developed by FACIT portfolio company Cellular Analytics
January 27, 2022 – FACIT congratulates portfolio company Cellular Analytics on a recent publication by its CSO, Dr. Shana Kelley and collaborators, on the Company’s tumor-infiltrating lymphocyte (TIL) therapeutics platform. Read More
